Joyce A. Schroeder, PhD, an associate professor in the Department of Molecular and Cellular Biology at the University of Arizona, a Galileo Circle Fellow in the College of Science and an Arizona Cancer Center and BIO5 Institute member, has been awarded a US patent for a first-in-class breast cancer treatment.
PMIP (which stands for Protein Transduction Domain 4, MUC1 Inhibitory Peptide) is designed to block the interaction of two proteins in cells which cause breast cancer to grow and spread. PMIP targets cancer-specific interactions and has shown no toxicity to normal cells in preclinical tests.
MUC1, an oncogene, is overexpressed in more than 90 percent of breast cancer patients, so blocking this molecule’s progression from the initial tumor will keep the cancer from spreading to other parts of the body. The epidermal growth factor receptor, or EGFR, family of proteins makes up a crucial aspect of oncology because it signals not only growth but disregulated growth, or, often, cancer.
“This drug goes into the cell and separates the proteins and puts them back where they belong,” Dr. Schroeder explains.
“Typically, metastatic breast cancer resists therapy. With this drug, we have a strong chance of saving women’s lives,” she says.
This peptide drug not only blocks the spread of a tumor but reduces its size. “We are hopeful that it may treat patients without the terrible side effects associated with chemotherapy,” Dr. Schroder said.
Dr. Schroeder says the patent will help move the drug closer to the bedside from the laboratory bench. She and her team are seeking grants to move the drug into clinical trials
The patent process started in summer 2004. The Arizona Biomedical Research Commission has funded Dr. Schroeder’s work for six years and it also funded the patent application activities. ABRC recently awarded Dr. Schroeder $337,500 to investigate new targets in a similar manner to PMIP.
Aug. 18, 2010